ArticleArthritis research & therapy2024
Risk prediction of new-onset thrombocytopenia in patients with systemic lupus erythematosus: a multicenter prospective cohort study based on Chinese SLE treatment and research group (CSTAR) registry.
Article in Arthritis research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hematologic Involvement in Systemic Lupus Erythematosus: Clinical Features and Prognostic Implications in a Hematology-Referred Cohort.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThrombocytopenia (TP) is a hematological manifestation of systemic lupus erythematosus (SLE) and is associated with unfavorable prognostic outcomes. This study aimed to develop a risk prediction model for new-onset TP in SLE patients.
methodsBased on the multicenter prospective Chinese SLE Treatment and Research Group (CSTAR) registry, newly diagnosed SLE patients without TP at registration were enrolled. The least absolute shrinkage and selection operator (LASSO) method was used for variable selection. The final model was developed using multivariate Cox regression and displayed as a nomogram. Internal validation was achieved using enhanced Bootstrap resampling.
resultsDuring follow-up, thrombocytopenia developed in 80 (3.52%) of 2270 lupus patients. The final risk prediction model incorporated six predictors: baseline SDI score ≥ 1 (HR 2.207, 95% CI 1.350-3.609, p = 0.002), hemolytic anemia (HR 1.953, 95% CI 1.017-3.750, p = 0.044), low complement level (HR 2.351, 95% CI 1.004-5.505, p = 0.049), positive anti-β2GPI antibody (HR 1.805, 95% CI 1.084-3.004, p = 0.024), positive Coombs test (HR 1.878, 95% CI 1.123-3.141, p = 0.017), and positive anti-histone antibody (HR 1.595, 95% CI 1.017-2.587, p = 0.059). The model's performance was indicated by C-index values for risk prediction at one, two, and three years, which were 0.741 (0.660-0.823), 0.730 (0.655-0.805), and 0.710 (0.643-0.777), respectively; and Brier scores of 0.018 (0.012-0.024), 0.025 (0.017-0.032), and 0.037 (0.027-0.046), respectively. Calibration curves were drawn and situated near the diagonal line.
conclusionsThis study developed the first risk prediction model for TP onset in lupus patients. Patients with baseline organ damage, hemolytic anemia, low complement, positive anti-histone antibody, positive anti-β2GPI antibody, or positive Coombs test were identified as being at high risk for thrombocytopenia and require further clinical attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.